Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder

Pan, Chin-Chen; Chang, Yen-Hwa; Chen, Kuang-Kuo; Yu, Hui-Jung; Sun, Chih-Hao; Ho, Donald Ming‐Tak

doi:10.1136/jcp.2010.079764

Cited by 30 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, the number of high grade tumours (85 patients) was low and their clinical characteristics were not clearly described. Pan et al [18] analysed a reliable series of 2191 patients with NMIBC and concluded that grade was the only prominent prognostic factor in multivariate models. Although their study did not show differences in terms of progression and cancer-specific mortality when comparing low grade pTa and pT1 stages, the role of grade for the patients with high grade tumours could not be determined.…”

Section: Discussionmentioning

confidence: 99%

Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non‐muscle‐invasive bladder cancer. A step forward or back?

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo compare the clinical reliability of the 1973 and 2004 World Health Organisation (WHO) classification systems in pT1 bladder cancer. Patients and MethodsWe retrospectively evaluated 291 consecutive patients who had pT1 high grade bladder cancer between 2004 and 2011. All tumours were simultaneously evaluated by a single uro-pathologist as high grade and G2 or G3. All patients underwent a second transurethral resection (TUR) and those confirmed with non-muscle-invasive bladder cancer at second TUR received bacille Calmette-Guérin. Follow-up included urine cytology and cystoscopy 3 months after second TUR and then every 6 months for 5 years. Univariate and multivariate analysis to determine recurrence-free survival (RFS) and progression-free survival (PFS) rates were performed using the Kaplan-Meier method with the log-rank test. ResultsG2 tumours were found in 124 (46.6%) and G3 in 142 (53.4%) patients. The mean (median; range) follow-up period was 31.1 (19; 1-93) months. The 5-year RFS rate was 39.1% for the overall high grade population, and 49.1 and 31.8% for G2 and G3 subgroups, respectively. The 5-year PFS was 82% for the overall high grade population and 89 and 73% for G2 and G3 subgroups, respectively. RFS (P < 0.002) and PFS (P < 0.001) rates were significantly different between the G2 and G3 subgroups. In multivariate analysis, only the grade assessed according to the 1973 WHO significantly correlated with both RFS (P = 0.003) and PFS (P < 0.001). ConclusionThe results suggest that the 1973 WHO classification system has higher prognostic reliability for patients with T1 disease. If confirmed, these findings should be carefully taken into account when making treatment decisions for patients with T1 bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non‐muscle‐invasive bladder cancer. A step forward or back?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This is clinically important because there were significant differences in the progression and cancer-specific mortality cumulative incidence between the low-and the high-grade papillary urothelial carcinomas. 31 The earlier detection of genitourinary cancer in patients with OAT may be explained by the OAT-enhanced bleeding in patients with low-grade lesions that otherwise would not have been diagnosed. This hypothesis is supported by the most common genitourinary malignancy and was significantly more common in the OAT(+) group than in the OAT(−) group.…”

Section: Oat and The Detection Of Genitourinary Cancermentioning

confidence: 99%

Clinical Significance of Hematuria in Atrial Fibrillation With Oral Anticoagulation Therapy

Kim

Uhm

et al. 2017

Circ J

View full text Add to dashboard Cite

Background: Hematuria is a common and important complication in atrial fibrillation (AF) patients on oral anticoagulation therapy (OAT). This study evaluated the clinical significance of hematuria and its relationship with genitourinary disease in AF patients receiving OAT. Methods and Results:Among 20,456 consecutive AF patients who visited a tertiary hospital from January 2005 to April 2015, 5,833 had hematuria. Of these 5,833 patients, 3,798 were on OAT (OAT(+) group) and 2,035 were not (OAT(-) group). A total of 1,785 patients from each group were then matched on propensity score analysis. The prevalence of cancer and other diseases in the genitourinary tract was evaluated. While there was no difference in the prevalence of genitourinary stones or urinary tract infection, genitourinary cancer was significantly more common in the OAT(+) group than in the OAT(-) group (1.6% vs. 0.7%, P=0.011). Bladder cancer was the most common genitourinary malignancy, and it was significantly more common in the OAT(+) group (1.2% vs. 0.5%, P=0.019). Subjects on warfarin were more likely to have bladder cancers of lower pathologic grade (63.6% vs. 33.3%, P=0.124). Conclusions:OAT was associated with a higher prevalence and early detection of genitourinary cancer in AF patients with hematuria. Meticulous evaluation of the cause of hematuria is necessary in AF patients with hematuria receiving OAT.

show abstract

“…6,7 In multiple studies, the WHO/ISUP consensus classification system has been demonstrated to be significantly associated with clinical outcome. 2,[32][33][34]37,42,43,51,59 It has long been known that canine urothelial neoplasms are similar to urothelial neoplasms in humans in terms of morphology, biological behavior, and response to chemotherapy. 14,18,19,27,28,59 Patrick et al recently examined the potential use of the WHO/ISUP consensus classification system in classifying canine proliferative urothelial lesions.…”

Section: Introductionmentioning

confidence: 99%

Differences in Expression of Uroplakin III, Cytokeratin 7, and Cyclooxygenase-2 in Canine Proliferative Urothelial Lesions of the Urinary Bladder

et al. 2014

View full text Add to dashboard Cite

The expression of immunohistochemical markers that have been used in diagnosis and/or prognostication of urothelial tumors in humans (uroplakin III [UPIII], cytokeratin 7 [CK7], cyclooxygenase-2 [COX-2], and activated caspase 3) was evaluated in a series of 99 canine proliferative urothelial lesions of the urinary bladder and compared to the lesion classification and grade as defined by the World Health Organization / International Society of Urologic Pathology consensus system. There were significant associations between tumor classification and overall UPIII pattern (P ¼ 1.49 Â 10 -18 ), loss of UPIII (P ¼ 1.27 Â 10 -4 ), overall CK7 pattern (P ¼ 4.34 Â 10 -18 ), and COX-2 pattern (P ¼ 8.12 Â 10 -25). In addition, there were significant associations between depth of neoplastic cell infiltration into the urinary bladder wall and overall UPIII pattern (P ¼ 1.54 Â 10 ). There were no significant associations between tumor classification or infiltration and caspase 3 expression pattern.Keywords dog, urinary bladder, oncology, immunohistochemistry, transitional cell carcinoma, uroplakin III, neoplasia, cytokeratin Proliferative lesions of the urothelium of the canine urinary bladder range from benign polyps and papillomas to carcinomas with varying metastatic potential. Also, inflammatory conditions such as polypoid cystitis can form tumor-like masses within the urinary bladder that can be confused with urothelial neoplasms. Classification of urothelial proliferative lesions and histologic grading of urothelial carcinomas is key to accurate prognostication and treatment selection. A classification and grading scheme based on the 1986 World Health Organization (WHO) classification scheme for human urinary bladder and urethral cancer was proposed in 1995 for use in evaluating urothelial neoplasms in dogs based on pattern of growth, nuclear atypia, and degree of infiltration into the urinary bladder wall. 50 In the initial description of this system's use in dogs, significant correlations were found between tumor grade and depth of infiltration, the presence of metastases, and survival time. However, a subsequent smaller study failed to find a significant correlation between grade and prognosis. 41 To our knowledge, this scheme is not widely used in dogs and has been replaced in human medicine by more modern classification schemes. There remains a need for a clear, reproducible, and well-accepted classification and grading scheme for urothelial proliferative lesions in dogs.Currently, the most widely accepted scheme for classification and grading of proliferative urothelial lesions in humans is the WHO / International Society of Urologic Pathology (ISUP) consensus classification system, published in 1998 and updated in 2004. 6,7 In multiple studies, the WHO/ISUP consensus classification system has been demonstrated to be significantly associated with clinical outcome. 2,[32][33][34]37,42,43,51,59 It has long been known that canine urothelial neoplasms are similar to urothelial neoplasms in humans in terms o...

show abstract

Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder

Abstract: Robust nomograms were created to predict PFS and CSS. These data provide an overall perspective of disease outcomes which may aid in developing individualised follow-up programmes.

Cited by 30 publications

References 25 publications

Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non‐muscle‐invasive bladder cancer. A step forward or back?

Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non‐muscle‐invasive bladder cancer. A step forward or back?

Clinical Significance of Hematuria in Atrial Fibrillation With Oral Anticoagulation Therapy

Differences in Expression of Uroplakin III, Cytokeratin 7, and Cyclooxygenase-2 in Canine Proliferative Urothelial Lesions of the Urinary Bladder

Contact Info

Product

Resources

About